Description
Pre-Congress event:
This one-day consensus conference is taking place the day before EASL Congress 2025 in Amsterdam.
The event is aimed to integrate the current knowledge in trial design and endpoints in HCC and provide a new frame for ongoing and future trial in the field of HCC. A review of the current management and novel therapeutical approaches will be provided.
Date and time: 6 May, 9:00-17:30 CEST
Steering Committee: Josep M. Llovet (Chair), Richard Finn (Co-chair), Tim Meyer (Co-chair), Amit Singal (Co-chair), and Arndt Vogel (Co-chair).
Registration:
Registration is required to attend the pre-congress event “Trial design and end-points in HCC”. Please note that the pre-conference event is only accessible for onsite participants. There will be no live-stream available and online delegates will not be able to attend.
Registration fee:
EUR 102.85 (EUR 85 plus 21% Dutch VAT)
Registration process:
- Go to the EASL Congress 2025 registration platform.
- Login with your account or create a new account.
- Select “Individual Registration”
- Click “Next” to accept the Terms & Conditions.
- Select “Register or book tickets for yourself” or “Register or book ticket for someone else” to proceed.
- Select “Participant type”. Add your EASL Membership number if appropriate, and click “Choose tickets” to proceed.
- Add “discount code” if applicable, and click “Next” to proceed.
- Select tickets:
- If you wish to register for both EASL Congress 2025 and the pre-congress event “Trial design and end-points in HCC” please select both tickets.
- If you have already register for EASL Congress 2025 or wish to only register for the pre-congress event “Trial design and end-points in HCC” please only select the applicable ticket.
- Complete all other required fields and proceed to payment to confirm your registration.
Questions:
For registration queries, please contact: EASLcongress.registration@easloffice.eu
Learning objectives
- Review the current trial design and end points in early, intermediate and advanced HCC, and the need for a new agreement considering the outcomes of recent RCT.
Recommendations will be focused on phase II and III trials. - Review how biomarkers can be integrated in the management of HCC along with tumor biopsies and circulating ct DNA assays in guiding therapeutic decision-making.
- Review the armamentarium of therapies available and anticipate the potential role of triplet regimens, cell therapies, vaccines and other novel approaches.
- Understand the views of academia, regulatory agencies and patients about criteria for defining clinical benefit and potential regulatory approval.
Methodology
First, the panelists will provide a draft document with recommendations prior to the meeting on June 2025.
During the meeting, all recommendations will be analyzed. In principle, the panel would explore achieving a consensus agreement, although in special circumstances a majority decision might prevail. In these cases, a minority report will be included in the document.
Afterwards each co-chair will seek the endorsement of each scientific society according to the internal procedures. A final document capturing potential changes will be prepared for submission to Nature Reviews Clinical Oncology by the end of 2025.
Target Audience
- Hepatologists
- Physician Assistants
- Oncologists
- Transplant Coordinators
- Surgeons
- Fellows/Trainees
- Radiologists
- Government/Regulatory Representatives
- Nurses
- Pharmacists
- Industry